Vestor Capital LLC Has $347,000 Holdings in Stryker Co. (NYSE:SYK)

Vestor Capital LLC increased its stake in Stryker Co. (NYSE:SYK) by 208.5% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,160 shares of the medical technology company’s stock after buying an additional 784 shares during the quarter. Vestor Capital LLC’s holdings in Stryker were worth $347,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in the stock. Farmers & Merchants Trust Co of Chambersburg PA raised its stake in Stryker by 203.3% in the 4th quarter. Farmers & Merchants Trust Co of Chambersburg PA now owns 91 shares of the medical technology company’s stock valued at $27,000 after acquiring an additional 61 shares during the period. Rogco LP bought a new position in Stryker during the 4th quarter worth $30,000. HBC Financial Services PLLC bought a new position in Stryker during the 4th quarter worth $37,000. Bourgeon Capital Management LLC bought a new position in Stryker during the 4th quarter worth $37,000. Finally, Operose Advisors LLC increased its position in Stryker by 308.6% during the 3rd quarter. Operose Advisors LLC now owns 143 shares of the medical technology company’s stock worth $39,000 after buying an additional 108 shares during the period. Institutional investors and hedge funds own 77.09% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on SYK shares. Canaccord Genuity Group upgraded Stryker from a “hold” rating to a “buy” rating and increased their price objective for the stock from $315.00 to $360.00 in a research report on Wednesday, January 31st. UBS Group boosted their price target on Stryker from $339.00 to $351.00 and gave the company a “neutral” rating in a research note on Wednesday, May 1st. StockNews.com raised Stryker from a “hold” rating to a “buy” rating in a research note on Tuesday, January 23rd. Evercore ISI boosted their price target on Stryker from $340.00 to $370.00 and gave the company an “outperform” rating in a research note on Thursday, April 4th. Finally, Citigroup boosted their price target on Stryker from $362.00 to $406.00 and gave the company a “buy” rating in a research note on Wednesday, April 3rd. Four investment analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $365.94.

Stryker Trading Up 0.5 %

SYK traded up $1.58 during trading on Thursday, hitting $330.86. The company’s stock had a trading volume of 980,396 shares, compared to its average volume of 1,327,501. Stryker Co. has a twelve month low of $249.98 and a twelve month high of $361.41. The company has a quick ratio of 0.99, a current ratio of 1.71 and a debt-to-equity ratio of 0.56. The stock’s fifty day moving average price is $345.60 and its 200-day moving average price is $318.91. The firm has a market capitalization of $126.04 billion, a P/E ratio of 37.77, a PEG ratio of 2.54 and a beta of 0.91.

Stryker (NYSE:SYK) last issued its quarterly earnings results on Tuesday, April 30th. The medical technology company reported $2.50 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.36 by $0.14. Stryker had a return on equity of 23.05% and a net margin of 16.03%. The firm had revenue of $5.24 billion for the quarter, compared to analyst estimates of $5.10 billion. During the same period in the previous year, the firm earned $2.14 earnings per share. The company’s revenue was up 9.7% compared to the same quarter last year. Analysts anticipate that Stryker Co. will post 11.94 EPS for the current year.

Insider Transactions at Stryker

In other news, CAO William E. Berry, Jr. sold 7,690 shares of the company’s stock in a transaction that occurred on Thursday, March 7th. The stock was sold at an average price of $358.48, for a total transaction of $2,756,711.20. Following the transaction, the chief accounting officer now directly owns 3,675 shares of the company’s stock, valued at $1,317,414. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 5.50% of the stock is owned by insiders.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.